LB Pharmaceuticals Inc Common Stock (LBRX) vs MoonLake Immunotherapeutics (MLTX)
A side-by-side comparison of LB Pharmaceuticals Inc Common Stock and MoonLake Immunotherapeutics across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
LBRX
LB Pharmaceuticals Inc Common Stock
$34.22HealthcareDelayed quote: Oct 6, 2026, 3:35 PM EDT
MLTX
MoonLake Immunotherapeutics
$11.00HealthcareDelayed quote: Oct 6, 2026, 3:30 PM EDT
Total return — LBRX vs MLTX
growth of $100 · dividends reinvested · last 1yLBRX +100.1% (+100.1%/yr)MLTX -79.0% (-79.0%/yr)LBRX compounded faster over this window
Log scale — wide-divergence pair
LBRX MLTX
LBRX vs MLTX: by the numbers
- •LBRX is the larger company ($981M vs $925M market cap).
Metrics side by side
Valuation
| Metric | LBRX | MLTX |
|---|---|---|
| P/B ratio | 2.95 | 2.16 |
Profitability
| Metric | LBRX | MLTX |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -25.78% | -61.58% |
| ROIC | -28.14% | -50.77% |
Growth (annualized)
| Metric | LBRX | MLTX |
|---|---|---|
| Total return CAGR (5Y) | N/A | 2.81% |
Go deeper
Dig into the metrics
LB Pharmaceuticals Inc Common Stock ROEMoonLake Immunotherapeutics ROELB Pharmaceuticals Inc Common Stock operating marginMoonLake Immunotherapeutics operating marginLB Pharmaceuticals Inc Common Stock revenue growthMoonLake Immunotherapeutics revenue growthLB Pharmaceuticals Inc Common Stock free cash flowMoonLake Immunotherapeutics free cash flow
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.